(Q51995714)

19 April 2018

title

Mixed Anxiety and Depression : Diagnosis and Treatment Options. (English)

1 reference

19 April 2018

author name string

D Bakish

series ordinal

1

1 reference

19 April 2018

R Habib

series ordinal

2

1 reference

19 April 2018

C L Hooper

series ordinal

3

1 reference

19 April 2018

publication date

1 April 1998

1 reference

19 April 2018

published in

CNS Drugs

1 reference

19 April 2018

volume

9

1 reference

19 April 2018

issue

4

1 reference

19 April 2018

page(s)

271-280

1 reference

19 April 2018

https://scigraph.springernature.com/pub.10.2165/00023210-199809040-00003

exact match

0 references

cites work

Response of anxiety and agitation symptoms during nefazodone treatment of major depression

1 reference

12 December 2020

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

12 December 2020

The prevalence of psychiatric disorders in a primary care practice.

1 reference

12 December 2020

[Sertraline in the treatment of mixed anxiety and depression disorder]

1 reference

12 December 2020

Pharmacological treatment of depression and comorbid anxiety disorders.

1 reference

12 December 2020

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

12 December 2020

Recurrent brief depression: a new subtype of affective disorder

1 reference

12 December 2020

Mixed anxiety and depression: diagnostic issues.

1 reference

12 December 2020

Emergence of depressive symptoms in patients receiving alprazolam for panic disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

12 December 2020

Efficacy of moclobemide in different patient groups: a meta-analysis of studies

1 reference

12 December 2020

Frequency of symptoms in melancholia (depressive illness)

1 reference

12 December 2020

Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia.

1 reference

12 December 2020

Depression and generalized anxiety symptoms in panic disorder. Implications for comorbidity.

1 reference

12 December 2020

Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.

1 reference

12 December 2020

Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

1 reference

12 December 2020

Use of low-dose fluoxetine in major depression and panic disorder

1 reference

12 December 2020

How to manage anxious patients who are depressed

1 reference

12 December 2020

Open trial of buspirone in the treatment of major depressive disorder.

1 reference

12 December 2020

Efficacy of venlafaxine in depressive illness in general practice

1 reference

12 December 2020

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients

1 reference

12 December 2020

Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence?

1 reference

12 December 2020

The anti-anxiety and anti-agitation effects of paroxetine in depressed patients

1 reference

12 December 2020

Antidepressant specificity in atypical depression.

1 reference

12 December 2020

Buspirone in the management of major depression: a placebo-controlled comparison.

1 reference

12 December 2020

Further evidence on the doubtful validity of generalized anxiety disorder

1 reference

12 December 2020

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

1 reference

12 December 2020

Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness

1 reference

12 December 2020

DSM-III generalized anxiety disorder: an empirical investigation of more stringent criteria.

1 reference

12 December 2020

A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice

1 reference

12 December 2020

Effect of panic attacks on the treatment of atypical depressives

1 reference

12 December 2020

The treatment of generalized anxiety disorder in patients with depressive symptomatology.

1 reference

12 December 2020

Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms

1 reference

12 December 2020

Neurotic illness and its response to anxiolytic and antidepressant treatment.

1 reference

12 December 2020

The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia

1 reference

12 December 2020

Coexisting depression and anxiety: special diagnostic and treatment issues

1 reference

12 December 2020

Reversible monoamine oxidase-A inhibitors in panic disorder

1 reference

12 December 2020

Anxiety symptom relief in depression treatment outcomes

1 reference

12 December 2020

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

1 reference

12 December 2020

A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia

1 reference

12 December 2020

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

1 reference

12 December 2020

Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms

1 reference

12 December 2020

Tranylcypromine in social phobia.

1 reference

12 December 2020

Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey

1 reference

12 December 2020

The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings

1 reference

12 December 2020

An open-label trial of nefazodone in high comorbidity panic disorder

1 reference

12 December 2020

Mixed anxiety and depression: clinical implications

1 reference

12 December 2020

The safety profile of nefazodone

1 reference

12 December 2020

Amitriptyline in Anxious-Depressed Outpatients: A Controlled Study

1 reference

12 December 2020

Depressive symptoms and depressive diagnoses in a community population. Use of a new procedure for analysis of psychiatric classification

1 reference

12 December 2020

Fluoxetine treatment of social phobia

1 reference

12 December 2020

Nefazodone: aspects of efficacy

1 reference

12 December 2020

The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis.

1 reference

12 December 2020

Mixed anxiety and depression

1 reference

12 December 2020

Management of comorbid anxiety and depression.

1 reference

12 December 2020

Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine

1 reference

12 December 2020

10.2165/00023210-199809040-00003

Identifiers

DOI

1 reference

19 April 2018

Dimensions Publication ID

1008899454

0 references

1 reference

19 April 2018